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Review of the Literature
Fibromyalgia Syndrome: Considerations for Dental
Hygienists
Amber Walters, BSDH, MS; Susan L. Tolle, BSDH, MS; Gayle M. McCombs, BSDH, MS

Introduction

Abstract

Fibromyalgia syndrome (FMS) is a
Purpose: Fibromyalgia syndrome (FMS) is a neurosensory disorneurosensory disorder of unknown
der characterized by widespread musculoskeletal pain. Typically
etiology characterized by chronic
persistent fatigue, depression, limb stiffness, non-refreshing sleep
musculoskeletal pain, fatigue, tenand cognitive deficiencies are also experienced. Oral symptoms
derness and sleep disturbances.
and pain are common, requiring adaptations in patient manageFMS can result in severe disability
ment strategies and treatment interventions. Appropriate dental
and loss of function, leading to dehygiene care of patients suffering with this disorder is contingent
creased quality of life.1 This disorder
upon an understanding of disease epidemiology, pathophysiology,
can affect any aspect of an individclinical characteristics, oral signs and symptoms, as well as treatual’s body, including the oral cavity,
ment approaches. With this information dental hygienists will be
and adverse orofacial conditions are
better prepared to provide appropriate and effective treatment to
common. Modifications in dental hypatients with FMS.
giene treatment are often needed
Keywords: fibromyalgia, oral hygiene, orofacial pain, special
to ensure patient comfort and opneeds, medically complex patients
timum treatment. In addition, oral
This study supports the NDHRA priority area, Clinical Dental Hycare practitioners may identify early
giene Care: Assess the use of evidence-based treatment recomsymptoms of FMS, assisting the pamendations in dental hygiene practice.
tient in receiving a proper diagnosis.
Appropriate dental hygiene management requires an understanding of
disease characteristics and pathophysiology, oral der points. Instead, the criteria requires a detailed
health considerations and treatment interventions. interview to evaluate total body pain using a Widespread Pain Index, as well as a measurement of
Epidemiology
symptom severity, known as the Symptom Severity scale.16 To be diagnosed with FMS the criteria
FMS is the second most common diagnosis found in Figure 1 must be met.
made by rheumatologists and is estimated to affect 3 to 6% of the population worldwide.2,3 FMS
The most predominant symptom of FMS is chroncan affect anyone regardless of age, gender or ic, widespread musculoskeletal pain, described as
ethnicity; however 75 to 90% of people diagnosed being persistent, deep, aching and/or throbbing.
are women.3 Prevalence of fibromyalgia is higher Hyperalgesia (exaggerated or prolonged response
at middle age (30 to 50 years) or over the age of to stimuli), dysesthesia (unpleasant, abnormal
50.4-13 The worldwide incidence of FMS is 6.88 per sense of touch) and allodynia (perception of pain
1,000 males and 11.28 per 1,000 females.14 The to a non-painful stimulus) are also common findincidence may be increasing and is linked to in- ings.17,18 Some people experience uniform pain all
creased disease awareness among physicians.
day long, while others report pain that is worse in
the morning, improves during the day and worsens
Basic Characteristics
again at night. Pain associated with FMS can be
exacerbated by physical or emotional stress, nonThe 1990 American College of Rheumatology restorative sleep, strenuous activity and changes
classification criteria for FMS included a history of in weather.18,19
chronic, diffuse pain affecting 4 quadrants of the
body for at least 3 months and pain upon palpation
Fatigue, cognitive deficiency, tenderness upon
in at least 11 out of 18 tender points.15 In 2010, mild palpation and non-restorative sleep are comthe American College of Rheumatology revised mon manifestations often accompanied by a wide
this criterion, eliminating the need to assess ten- array of additional symptoms listed in Figure 2.20,21
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The onset of symptoms can appear suddenly; however, they are generally experienced gradually.20,22
Common psychiatric and medical comorbidities
may also be present (Figure 3).18,21
Diseases of fatigue and widespread pain have
similar signs and symptoms making the diagnosis of FMS difficult. Lyme disease, hypothyroidism,
rheumatoid arthritis, systemic lupus and undiagnosed cancer are often confused with FMS (Figure
4).18,22 Because there are no objective laboratory
or radiographic tests to definitively diagnose FMS,
patients often report a long delay between onset
of symptoms and a diagnosis.1
Sleep disturbances reported include non-restorative sleep, insomnia and poor quality of sleep.23
Munguia-Izquierdo and Legaz-Arrese revealed the
prevalence of poor sleep quality was 96% in patients with FMS compared to 46% for healthy subjects.24 Quality of sleep was much lower in patients
with FMS compared to controls and poor sleep
quality was strongly associated with pain and fatigue.24
FMS can result in severe disability and loss of
function, making daily tasks, including oral selfcare, difficult or unmanageable.1,19,25 Research
by Bennett et al suggests people with FMS have
difficulty with routine activities such as walking
2 blocks (55%), climbing stairs (62%), shopping
(66%), household chores (68%) and carrying 10
pounds (70%).19 The debilitating effects of FMS can
also be seen in the work place. Decreased ability
to function leads to loss in productivity, increased
work absenteeism and an overall decreased quality
of life.26 In fact, working adults with FMS miss an
average of almost 17 days of work annually compared to 6 days for those without the syndrome.27
Fatigue, inability to concentrate, decreased motivation, and low self-efficacy may contribute to
poor job performance.
Depression, anxiety, stress and impaired cognitive function are common psychological findings in
patients with FMS. Bennett el al found 38% of FMS
patients reported anxiety and 40% reported depression.19 These psychological disturbances may
be related to coping with the debilitating effects
and chronic pain of FMS, rather than a primary
symptom.28 Cognitive deficiency in people with
FMS is sometimes called “fibro fog” and includes
short-term memory loss, reduced mental alertness
and decreased ability to multitask.18,21
Pathophysiology

Figure 1: 2010 Fibromyalgia Syndrome Diagnostic Criteria16
Criteria:
A patient meets the diagnostic criteria for FMS if these
3 conditions are met:
• Widespread pain index ≥7 and symptom severity
scale score ≥5 or Widespread Pain Index 3 to 6  
and Symptom Severity scale score ≥9
• The patient has been experiencing symptoms at a
similar level for 3 months or longer
• The patient does not have any other condition that
would explain the pain
Scoring:
Widespread Pain Index: Count the number of regions
the patient reports pain within the last week
• Score will range 0 to 19.
Symptom Severity Scale Score*: Indicate how severe
each of these 3 symptoms (fatigue, waking unrefreshed, cognitive symptoms) have been over the past
week using the following scale:
• 0 - No problem
• 1 - Slight or mild problems
• 2 - Moderate, often present and/or at a moderate
level
• 3 - Severe, continuous, life-disturbing problems
Considering common other symptoms, note whether
the patient has:
• 0 - no symptoms
• 1 - few symptoms
• 2 - a moderate amount of symptoms
• 3 - many symptoms
*The Symptom Severity scale score is the sum of the severity of the 3 symptoms (fatigue, waking unrefreshed,
cognitive symptoms) and the extent of the other symptoms in general. Score will be between 0 and 12.

Figure 2: Symptoms of Fibromyalgia Syndrome16
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FMS is linked to a multifactorial etiology.22 SusVol. 89 • No. 2 • April 2015
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Figure 3: Comorbidities of Fibromyalgia Figure 4: Differential Diagnoses for FibroSyndrome18,21
myalgia Syndrome18,22
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pected causes of FMS include abnormalities in pain
pathways, as well as genetic and environmental
factors.21-23 Cerebrospinal fluid substance P is a
neurotransmitter released when axons are stimulated. Consistently elevated in people with FMS,
this causes increased sensitivity and enhanced
awareness of pain.23,29 Substance P helps regulate
the responsiveness of N-methyl-D-aspartate receptors to the neurotransmitter glutamide, which
plays a role in central sensitization and temporal
summation.20,21 Concentration of substance P in
cerebrospinal fluid is 2 to 3 times higher in people
with FMS compared to control subjects.23,29 Substance P is involved in transmission of pain information from the periphery to the central nervous
system (CNS). Research suggests the combined
effect of low serotonin levels and high substance P
concentration, contribute to more pain than either
abnormality on their own, and this dual dysfunction may be responsible for the onset of FMS.21,30
The CNS is the predominant source of pain in
FMS. CNS sensitization, increased excitability of
neurons found in the spinal cord, makes neurons
more sensitive to stimuli. Central sensitization is
characterized by an exaggerated pain response,
prolonged duration of pain, increased pain intensity and wider pain distribution.21 A related phenomenon to sensitization is temporal summation,
called “wind-up,” which occurs when a stimuli is
applied repeatedly. With each repeated stimulation
there is a progressive increase in pain leading to
prolonged stimulation of C nerve fibers.21 Research
suggests levels of temporal summation from repetitive stimulation in people with FMS consistently exceed those of control subjects over a range of
stimulus frequencies.31,32 These phenomenon most
likely result in people with FMS exhibiting a lower
threshold of pain in response to stimuli.
A neuroendocrine system dysfunction involving
78
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virus (HIV)
infection
Hypothyroidism

Systemic lupus erythematosus

Lyme disease

Viral hepatitis

Multiple sclerosis

Vitamin and/or mineral
dificency

the abnormal functioning of the hypothalamic pituitary adrenal axis is linked to sleep disturbances
in patients with FMS.21,22 In response to stress, the
body secretes cortisol, and during chronic stress
the body continually increases secretion of this
chemical. In an effort to counteract the elevated
amount of cortisol, the negative feedback loop is
amplified which eventually leads to overcompensation and cortisol deficiency.22 This cortisol deficiency is most likely culpable in causing non-restorative sleep for FMS patients.22
Research has also linked abnormal levels of the
neurotransmitters serotonin, norepinephrine and
dopamine with FMS.2,20,22,23,30,33 Low serotonin levels are the most widely acknowledged biochemical
irregularity found in people with FMS and are of
particular interest due to their affect on delta sleep
and pain modulation.18,22,23,33-35 Serotonin and norepinephrine play a role in stopping pain response
by hindering pain pathways. When individuals with
FMS have decreased levels of these neurotransmitters their pain is prolonged.20,22 Dopamine plays
a critical role in modulating pain perception in the
CNS by inhibiting pain pathways and inducing natural analgesia during acute stress. During chronic
stress the body tries to restore homeostasis and
dopamine eventually becomes decreased due to
overcompensation of the negative feedback loop,
leading to a hyperalgesic state.
Both genetic and environmental factors may
be involved in the development of FMS. Research
suggests the high occurrence of FMS in families
may be attributed to genetic factors.36-38 Women
who have a relative with FMS are more likely to
have the syndrome; however, it is unclear whether
this is due to genetics, shared environmental factors or both.39
Environmental triggers such as mechanical or
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physical trauma and psychosocial factors have
been correlated with the development of FMS.33 A
study by Bennett et al suggests chronic stress is
the most perceived triggering event of FMS onset
(41%) followed by emotional trauma (31.3%).19
Trauma and stress may alter the pain modulatory
response in the brain, which could contribute to the
enhanced pain perception. Acute illness, serious
infection, physical injury, surgery, motor vehicle
accidents and other pain conditions are also commonly reported physical stressors.19,33 Psychosocial factors, such as a catastrophic event or abuse
(emotional, physical or sexual) have also been
associated with onset of symptoms.19,33 However,
research on the relationship between physical and
emotional abuse and the diagnosis of FMS have
been inconsistent.40,41 Havilan et al revealed a correlation between both sexual assault/abuse and
physical assault/abuse and FMS diagnosis; however, life-threatening trauma, emotional abuse/
neglect and major life stress were not found to be
associated with FMS diagnosis.42
Treatment
Treatment of FMS focuses on symptom management and improving quality of life. A holistic approach that integrates physical, psychological and
behavioral factors with the implementation of pharmacological and non-pharmacological strategies
is helpful in managing FMS.1-3,18-21,33,35 Medications
approved by the Food and Drug Administration for
the treatment of FMS include pregabalin (Lyrica®;
Pfizer, New York, NY), duloxetine (Cymbalta®; Eli
Lilly and Company, Indianapolis, Ind.), and milnacipran (Savella®; Forest Laboratories, New York,
NY ).1,3,21 Non–pharmacological therapies for treatment of FMS include patient education, exercise,
and cognitive behavioral therapy. Additionally,
acupuncture, hypnotherapy, balneotherapy (medicinal baths), biofeedback, ultrasound, relaxation
therapy and tender point injections have been reported as treatment options; however, evidence is
lacking to support the effectiveness of these therapies.18,33
Oral Concerns
Most patients with FMS report symptoms of
facial pain, including discomfort in the muscles
of mastication, temporomandibular joint (TMJ),
neck, ear and jaw.43 A study by Alonso-Blanco et
al investigated the differences in prevalence and
localization of referred pain areas of active trigger
points between 20 women with myofacial temporomandibular joint dysfunction (TMD) and 20 women
with FMS. Results revealed participants with FMS
had larger referred pain areas than those with TMD
Vol. 89 • No. 2 • April 2015

for the sternocleidomastoid and suboccipital muscles.44 Leblebici et al sought to determine the correlation between FMS, TMD and masticatory myofacial pain. A group of 31 people diagnosed with
FMS and a group of 21 people diagnosed with TMD
completed a questionnaire and underwent a clinical examination, which included bilateral manual
palpation of the masticatory muscles. The questionnaire consisted of questions about prior head
and neck trauma, parafunctional habits, muscle
fatigue, crepitus of the TMJ, restricted mandibular movement, jaw pain and prior TMD treatment.
Results revealed 80% of patients with FMS had
masticatory myofacial pain and TMD.45 This data
supports previous research that indicated the high
rate of involvement of the stomatognathic system in the course of FMS.46 Myofacial pain in fibromyalgic persons has also been noted in several
other studies, ranging from 40.9 to 85%.43,47,48 A
study by Pimentel et al revealed facial muscle pain
has been reported to be 31-times more prevalent
in people with FMS than those without the syndrome.43 Additionally, in a study conducted by
Fraga et al, masticatory muscle pain was reported
by 93.3% of people with FMS in at least one masticatory muscle.47 A study by Wolfe et al revealed
jaw pain specifically was self-reported by 35.4% of
individuals with FMS.49
Many patients with FMS also experience symptoms of TMD. A study by Pimentel et al investigated the prevalence of clinical features of TMD
in people with FMS. Forty women with FMS were
compared to 40 healthy controls using the Research Diagnostic Criteria for Temporomandibular
Disorders (RDC/TMD). Results indicated 77.5%
of the subjects with FMS met the diagnostic criteria for RDC/TMD Group I (muscle involvement)
compared to 10% of the control group.43 Previous
studies have also shown fibromyalgic persons have
a high prevalence of signs and symptoms of TMD,
ranging from 67.6 to 93.4%.45-48,50-52 Additionally,
studies suggest FMS may be a predisposing factor
for the onset of TMD,43,47,48,53,54 especially considering there are more individuals with FMS who have
TMD than people with TMD who have FMS.45,46
Routine treatments of TMD may not benefit people with FMS because the comorbidity of these 2
conditions may result from the alteration in pain
perception. Failure of the dental hygienist to acknowledge the underlying FMS diagnosis may lead
to lack of appropriate treatment. Occlusal splints
often recommended for patients suffering from
TMD, have not been shown to be beneficial for
treating myofacial pain in people with widespread
pain.55 However, tactile stimulation in the form of
massage has had a positive effect on clinical signs
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and subjective symptoms of TMD, as well as widespread pain in FMS patients who were unaffected
by routine TMD treatment.56
Additional oral manifestations prevalent in FMS
patients include limited mouth opening, pain upon
opening and masticatory pain.43,50 Muscle and joint
pain during opening and closing is prevalent with
FMS.43 The prevalence of limited mouth opening
has been reported to be 10 times higher in people
with FMS than controls with the average maximum
voluntary mouth opening for FMS patients at 41
mm, compared to 44 mm in the control group.43
The exact cause is unknown, but it is likely muscle
pain during jaw movements contributes to lower
range of motion during mouth opening.
Xerostomia is another common oral manifestation associated with FMS. Medications such as antidepressants, hypnotics, muscle relaxants, analgesics and anticonvulsants used to treat FMS may
contribute to xerostomia.17 A study by Rhodus et
al investigated the prevalence of oral symptoms in
patients diagnosed with FMS. Sixty-seven women
with FMS and matched controls completed a questionnaire and underwent an oral examination. The
questionnaire included questions about subjective symptoms of glossodynia (oral burning), xerostomia, dysphagia (difficulty swallowing), taste
abnormalities and TMD. Results revealed approximately 70% of subjects with FMS experienced
xerostomia.51 Only 27.5% of FMS subjects who
experienced xerostomia were taking xerogenic
medications, therefore research suggests a high
prevalence of xerostomia in this patient population even when controlling for xerostomia-inducing
medications.51 FMS patients may experience increased caries rate, periodontal disease, dysphagia, dysgeusia (distortion of taste), mouth ulcers
and candidiasis due to xerostomia.17
Glossodynia is commonly accompanied by xerostomia and dysgeusia and is experienced by approximately one-third of fibromyalgic persons.51
Glossodynia may represent hyperalgesia and allodynia resulting from nervous system sensitization.51 The neurological mechanisms responsible
for glossodynia may also contribute to chronic pain
in FMS. Treatment of glossodynia can be difficult
due its unknown etiology. Glossodynia is a side effect of certain medications; however, it may also
be caused by nutritional deficiencies, hormonal imbalances or depression.57 Tricyclic antidepressants
may benefit people with FMS and glossodynia because they can be used to treat depression, which
may play a role in the development of oral burning
and manage chronic pain.2,17,33,57
80

Figure 5: Orofacial Manifestations of Fibromyalgia Syndrome17,50
Xerostomia

Dysgeusia

Glossodynia

Dysphagia

Temporomandibular joint disorder (TMD)
Pain or fatigue in the orofacial region
Dysgeusia is also experienced by FMS patients.51
It is unclear whether dysgeusia represents a true
oral manifestation of FMS or is a side effect of
medications. Xerostomia can induce dysgeusia because normal salivary flow and concentration are
essential for taste. If dysgeusia is drug-induced,
patients can consult their physician about substituting another medication in place of the one causing taste disturbances.58
Patient Management
A detailed history of FMS should be documented including date of diagnosis, course of the syndrome and all current medications. Patients should
be questioned about orofacial pain and headaches
that may be indicative of TMD, as well as possible
oral manifestations of FMS including xerostomia,
glossodynia and dysgeusia (Figure 5). When performing an extraoral exam, the dental hygienist
should be cognizant of possible patient discomfort
in the regions of the TMJ and muscles of mastication. Additionally, if FMS is not diagnosed and
suspected, the dental hygienist should refer the
patient for further medical evaluation.17
Dental hygienists should consider adaptations during the process of care to ensure patient
comfort and an efficacious appointment. Patients
should be queried about what time of day they feel
best and scheduled accordingly. Many FMS patients experience pain and stiffness that is more
severe in the morning; therefore, a late morning
or early afternoon appointment may work best.
However, patients with FMS may cancel at the
last minute complaining of pain, fatigue or lack
of restful sleep. Additionally, FMS patients may
not be able to tolerate long appointments due to
jaw tiredness and pain. If possible, offer to break
up the patient’s treatment plan to accommodate
shorter appointments. To promote efficiency during the appointment, a dental hygiene assistant
and 4-handed dentistry is recommended. Patients
should also be asked to complete medical history forms prior to arrival. To conserve energy and
help prevent post exertional malaise following the
appointment, a disabled parking space should be
available and FMS patients should be treated in an
operatory close to the reception area.
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A stress-free treatment environment is ideal
since stress can exacerbate the pain response in
FMS patients.18,19 Strategies to help manage stress
during the appointment include developing a trusting relationship between the patient and the practitioner, effective pain management strategies,
and, for some patients, nitrous oxide-oxygen sedation. Muscle relaxants may also assist patients
with keeping the mouth open wider and more comfortably for a longer period of time also reducing
stress. Moreover, FMS patients may find breathing
or relaxation exercises helpful prior to and during
the dental hygiene appointment to reduce stress.
Preventing oral infection is important since infection increases stress on the body, which consequently exacerbates symptoms of FMS.19,50 Frequent recare appointments should be encouraged
to help prevent oral infection and monitor oral selfcare. Caution should be used when prescribing antibiotics, as they may increase therapeutic levels
of other medications FMS patients may be taking
such as citalopram (Celexa®; Forest Laboratories,
New York, NY) and zopiclone (Imovane®; SanofiAventis, Bridgewater, NJ).17 Some FMS patients
may benefit by taking anti-anxiety medication or
muscle relaxant prior to their dental hygiene appointment to help reduce emotional stress or anxiety. Since FMS patients often experience heightened pain sensitivity and fatigue, modifications
may be necessary to ensure patient comfort and
adequate pain management. Both topical and local
anesthetic agents are recommended to manage
discomfort during scaling and root debridement.
Anesthetic agents with vasoconstrictors should be
avoided for patients taking amitriptyline (Elavil®,
AstraZeneca, London, UK), venlafaxine (Effexor®,
Wyeth Pharmaceuticals, Madison, NJ) or duloxetine because they may create a hypertensive
crisis.17 Some patients may require intravenous
sedation for more extensive treatment. Prolonged
periods of jaw opening should be avoided and frequent breaks may be necessary for jaw rest. During dental hygiene care, practitioners will find a
mouth prop or bite block most effective as this can
provide additional support for those who have limited mouth opening or fatigue easily.
Because jaw pain may persist after the dental
hygiene appointment, FMS patients should be encouraged to eat a soft diet, use warm compresses
in the jaw region (unless heat exacerbates their
symptoms) and use analgesics such as tramadol
(Ultram®; Janssen Pharmapeuticals, Titusville,
NJ) or muscle relaxants such as cyclobenzaprine
(Flexiril®; McNeil Consumer and Specialty Pharmaceuticals, Fort Washington, Penn) and tizanidine
(Zanaflex®; Acorda Therapeutics, Ardsley, NY).17
Vol. 89 • No. 2 • April 2015

NSAIDs (e.g., aspirin and ibuprofen) should not
be recommended for patients taking selective serotonin reuptake inhibitors because they may increase the risk of prolonged bleeding.17
Patients with FMS are often hypersensitive
to stimuli such as noise, heat, cold, touch and
light.1,21,23 These normally non-painful stimuli may
produce pain for people with FMS. Therefore, patients should be consulted about the impact of
extraneous noise, such as background music,
televisions and powered scalers so these can be
eliminated or minimized if bothersome. A blanket or warm neck roll should be readily available
if the patient gets cold. A cervical pillow can be
used to support the neck better than the conventional dental chair headrest and reduce pressure
on tender points located on the back of the head
and neck. Additionally, since some FMS patients
experience hypersensitivity to light, oral care professionals should be conscientious of not shining
the dental light in the patient’s eyes and tinted
eyewear should be provided.
Patient Education
In order to reduce stress and improve FMS
symptoms, oral care professionals should encourage their patients to live a healthy lifestyle. Poor
nutrition can increase the production and secretion
of stress hormones and decrease the secretion of
insulin, which can lead to a lowered resistance to
infection such as periodontal disease.57 Dietary
counseling can be utilized when appropriate to promote healthy eating habits. Data suggests tobacco
smoking may exacerbate clinical features of FMS
patients.59,60 As part of encouraging a healthy lifestyle, tobacco cessation should be recommended.
Due to the debilitating effects of FMS and comorbidities, patients may have difficulty performing oral self-care. Extremities of FMS patients
often feel swollen, with upper extremities more
impacted than lower extremities; therefore, oral
self-care may be negatively affected.61 Additionally, FMS often co-occurs (up to 25 to 65%) with
other rheumatic conditions, and as a result of
these conditions, some patients may experience
dexterity issues.62 FMS patients with impaired
manual dexterity may find powered toothbrushes,
flossing devices and interdental brushes helpful.62
However, the noise from a powered device may be
a problem for FMS patients with heightened sensitivity to sound. Another option is the Surround®
toothbrush, which can be recommended if finances
or noise prevent the purchase or use of powered
devices or the patient fatigues easily.63 For some
patients, modifying the toothbrush by extend-
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ing or enlarging the handle may also be helpful.63
These modifications can also be performed on floss
handles and interdental brushes.
Depression is another common finding with FMS
patients that may have a negative effect on oral
health due to lack of self-care. Dental hygienists
should be compassionate and provide encouragement to FMS patients realizing self-care may not
always be a priority or may be difficult to accomplish. Clinicians must be cognizant of the psychological toll FMS takes on many individuals, as well
as its overall debilitating effects. Due to the high
prevalence of cognitive issues resulting in decreased mental alertness and memory (fibro fog),
patients may benefit from written self-care instructions and educational materials they can take
home to reinforce important concepts.
Patients should be educated on the difference
between the chronic, widespread FMS pain and
acute pain from an oral disease or infection. Patients may attribute dental pain to symptoms of
FMS and not seek immediate care, resulting in minor dental disease escalating to major. Therefore,
frequent recare intervals are critical to ascertain
oral disease status on a regular basis. Additionally,
with frequent recare, dental needs may be identified early, and be provided before more extensive
treatment is required, which may be difficult for
the patient to withstand.
Dental hygienists should encourage FMS patients with xerostomia to take an active role in
the management of their symptoms to minimize
risk of adverse oral effects. Strategies to help alleviate xerostomia include using saliva substitutes
and sialogogues, and avoiding alcohol and caffeine consumption. Saliva substitutes can be used
to replace moisture and lubricate the mouth for
short term relief. Sialogogues are any agent, over-
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the-counter or prescription, that aid in more long
term relief by stimulating new saliva. Prescription
sialogogues such as pilocarpine (Salagen®; Eisai,
Woodcliff Lake, NJ) and cevimeline (Evoxac®; Daiichi Sankyo, Parsippany, NJ) can be recommended
for patients who do not have medication-induced
xerotstomia. Chewing sugar free gum with xylitol
is also typically recommended for patients with xerostomia to stimulate salivary flow; however, many
FMS patients experience pain upon mastication
and therefore this management strategy would be
contraindicated. Xylitol mints and lozenges could
be suggested as they provide both caries benefit
and improve salivary flow without stressing masticatory muscles.

Conclusion
FMS is a common disorder that encompasses
symptoms of chronic, widespread musculoskeletal
pain, fatigue, cognitive deficiency and sleep disturbances. Oral manifestations of FMS are common and affect the oral and overall health of the
patient. Dental hygienists must be knowledgeable
about oral signs and symptoms of FMS in order to
educate their FMS patients on management strategies and oral self-care modifications. Additionally,
dental hygienists should be prepared to make appropriate adjustments when treating patients with
FMS to ensure hygiene care is rendered in a comfortable and effective manner.
Amber Walters, BSDH, MS, is an adjunct assistant professor. Susan L. Tolle, BSDH, MS, is a university professor. Gayle M. McCombs, BSDH, MS,
is a university professor and Graduate Program Director, Director, Dental Hygiene Research Center.
All are at Old Dominion University School of Dental
Hygiene.
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